Press release
Deadline on April 20th coming up in Lawsuit for Investors in shares of Immunovant, Inc. (NASDAQ: IMVT)
A Deadline is coming up on April 20, 2021 in the lawsuit for certain investors in Immunovant, Inc. (NASDAQ: IMVT).
Investors who purchased shares of Immunovant, Inc. (NASDAQ: IMVT) have certain options and there are strict and short deadlines running. Deadline: April 20, 2021. NASDAQ: IMVT stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Eastern District of New York the plaintiff alleges on behalf of purchasers of Immunovant, Inc. (NASDAQ: IMVT) common shares between October 2, 2019 and February 1, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between October 2, 2019 and February 1, 2021, the Defendants made false and/or misleading statements and/or failed to disclose that Health Sciences Acquisitions Corporation had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401, that IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA, that the foregoing foreseeably diminished IMVT-1401's prospects for regulatory approval, commercial viability, and profitability, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Immunovant, Inc. (NASDAQ: IMVT) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on April 20th coming up in Lawsuit for Investors in shares of Immunovant, Inc. (NASDAQ: IMVT) here
News-ID: 2260765 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for IMVT
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
Graves' Ophthalmopathy Therapeutics Market Size was ~USD 2,600 million in 2023, …
DelveInsight's "Graves Ophthalmopathy Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Graves Ophthalmopathy, historical and forecasted epidemiology as well as the Graves Ophthalmopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Graves Ophthalmopathy Market with DelveInsight's In-Depth Report @ Graves Ophthalmopathy Market Size- https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
Graves Disease Clinical Trials 2024: FDA Approvals, Mediction, Therapies, Treatm …
(Albany, United States) As per DelveInsight's assessment, globally, Graves Disease pipeline constitutes 8+ key companies continuously working towards developing 10+ Graves Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Graves Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graves Disease Market.
The Graves Disease Pipeline report embraces in-depth commercial…
Graves Ophthalmopathy Market: Examining Growth Prospects and Challenges, Patient …
DelveInsight's "Graves Ophthalmopathy Patient Pool Analysis, Market Size and Market Forecast APAC - 2034″ report offers an in-depth understanding of the Graves Ophthalmopathy, historical and forecasted epidemiology as well as the Graves Ophthalmopathy market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).
To Know in detail about the Graves Ophthalmopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graves Ophthalmopathy Market Forecast
https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some…
Investigation announced for NASDAQ: IMVT investors over possible Wrongdoing at I …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Immunovant, Inc..
Investors who are current long term investors in Immunovant, Inc. (NASDAQ: IMVT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: IMVT stocks follows a lawsuit filed against Immunovant, Inc. over…
Lawsuit filed for Investors in shares of Immunovant, Inc. (NASDAQ: IMVT)
An investor, who purchased shares of Immunovant, Inc. (NASDAQ: IMVT), filed a lawsuit over alleged violations of Federal Securities Laws by Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation.
Investors who purchased shares of Immunovant, Inc. (NASDAQ: IMVT) have certain options and for certain investors are short and strict deadlines running. Deadline: April 20, 2021. NASDAQ: IMVT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
New York…
